In the phase 2 EXTEND trial, investigators randomly assigned patients with oligometastatic prostate cancer to ADT or MDT + ADT, with further stratification by intermittent vs continuous ADT that was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback